Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01485588 · ClinicalTrials.gov registry record · Phase 1
Safety and Tolerability Study for Age-Related Macular Degeneration
A Phase 1 study of Neovascular Age-related Macular Degeneration, sponsored by Iconic Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 18
- Enrollment target
- 5
- Study locations
NCT01485588 is a Phase 1 study of Neovascular Age-related Macular Degeneration that has completed, run by Iconic Therapeutics. The registered enrollment target is 18 participants, below the 408-participant average among 33 other Neovascular Age-related Macular Degeneration trials with a reported enrollment target (96% lower). The trial reports 5 study locations across 4 states.
The verdict
NCT01485588, a Phase 1 study of Neovascular Age-related Macular Degeneration, has completed, sponsored by Iconic Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 18 participants
- Enrollment target
- 5
- Study locations
Study Summary
Phase 1: The purpose of this study is to evaluate the safety and tolerability of single ascending doses of hI-con1™ for subjects with Age-Related Macular Degeneration. Phase 2: The purpose of this study is to evaluate the safety of 3 injections of hI-con1™ at 2 different dose levels.
Conditions Studied
Interventions
- DRUG hI-con1™ 60µl
- DRUG hI-con1™ 150µl
- DRUG hI-con1™ 300µl
Study Locations (5)
Texas
- Retina Research Center - Austin
- Valley Retina Institute, PA - McAllen
Montana
- Rocky Mountain Eye Center, P.C. - Missoula
Oregon
- Retina & Vitreous Center of Southern Oregon, P.C. - Ashland
South Carolina
- Palmetto Retina Center - West Columbia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2010-12 |
| Est. Completion | 2012-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01485588
The ClinicalTrials.gov registry entry for NCT01485588 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 408-participant average among 33 other Neovascular Age-related Macular Degeneration trials with a reported enrollment target (96% lower). The listed sponsor is Iconic Therapeutics, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Neovascular Age-related Macular Degeneration appearing as the primary indexed condition, and to 3 interventions - of which hI-con1™ 60µl is the first listed.
NCT01485588 reports 5 study locations spanning 4 distinct geographic areas - top geographies include Texas, Montana, Oregon.
Frequently Asked Questions
What is clinical trial NCT01485588 about?
NCT01485588 is a clinical study titled "Safety and Tolerability Study for Age-Related Macular Degeneration". Phase 1: The purpose of this study is to evaluate the safety and tolerability of single ascending doses of hI-con1™ for subjects with Age-Related Macular Degeneration. Phase 2: The purpose of this study is to evaluate the safety of 3 injections of hI-con1™ at 2 different dose levels.
What is the current status of trial NCT01485588?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 18 participants. The study started on 2010-12. Estimated completion is 2012-03.
What conditions does trial NCT01485588 study?
This clinical trial studies the following conditions: Neovascular Age-related Macular Degeneration.
What interventions are being tested in trial NCT01485588?
The interventions under investigation include: hI-con1™ 60µl (DRUG), hI-con1™ 150µl (DRUG), hI-con1™ 300µl (DRUG).
Who is sponsoring clinical trial NCT01485588?
This trial is sponsored by Iconic Therapeutics, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01485588 being conducted?
This trial has 5 study locations across Montana, Oregon, South Carolina, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Neovascular Age-related Macular Degeneration
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Phase I/II Study of SKG0106 Intravitreal Injection in Patients With Neovascular Age-related Macular Degeneration (nAMD)
RECRUITING · Phase 1
-
A Safety and Efficacy Study of One-time SAR402663 in Adults With Neovascular Age-related Macular Degeneration
RECRUITING · Phase 1
-
Safety and Bioactivity of AXT107 in Subjects With Neovascular Age-Related Macular Degeneration (nAMD)
ACTIVE NOT RECRUITING · Phase 1
-
Effect of AIV007 by Periocular Administration in Subjects with Macular Edema Secondary to Neovascular Age-related Macular Degeneration (nAMD) and Diabetic Macular Edema (DME)
ACTIVE NOT RECRUITING · Phase 1
-
Evaluation of OLX10212 in Patients With Neovascular Age-related Macular Degeneration
COMPLETED · Phase 1
-
A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of IVT MHU650 in Macular Edema Patients
COMPLETED · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.